Index

A
Abuse
child abuse, 54, 107–109, 118, 123–124, 126, 128–130, 149, 170–172, 175
substance abuse, 28, 33, 54, 148
Acetyl-coenzyme A, 29
Acetylcholine, 90, 144
Adoption, 4, 186, 189–194, 198–203, 206–207
Adrenocorticotropic hormone (ACTH)
definition and physiology, 52
maternal effects, 104
non-human primate development and, 163, 165, 171, 175, 178
Aggression, 166, 167, 177, 194
Aging, 128, 200
Ainsworth, Mary, 118
Alcohol, 128–130, 179
Amblyopia, 3, 35–36, 49, 140
recovery in adult rodents, 15–18
AMP cyclic response element [CRE] binding Protein (CREB), 32, 34–38
AMPA receptors, 54, 78–79, 81
Amygdala, 53, 78, 86, 88, 174
institutionalization and, 196–197
maternal effects and, 120, 122–124, 127, 130
Angelman syndrome
cortical plasticity and, 79
gene deletion and, 86
MeCP2 and, 55
motor skills and, 74
mouse models and, 84
protein synthesis and, 82
Anisometropia, 15
Antidepressants
communal nesting and, 151
MeCP2 and, 58
neurotrophins and, 52–53, 149
see also benzodiazepine
Anxiety
BDNF and, 149
communal nesting and, 151
dependence on genotype, 174–175, 177–178
environmental enrichment and, 49
expression in infant primates, 163, 174–175, 177–178
maternal effects on, 100, 106, 126, 140, 141, 168, 170
relation with institutionalization, 192
Rett syndrome and, 55, 60
stress and, 52–53, 146
Apoptosis, 11, 143
Attention
Down syndrome and, 13
related disorders, 55, 189–190, 192, 194
institutionalization and, 197–199, 202, 205
Auditory cortex
environmental enrichment and, 13
Autism
adoption and, 190
benzodiazepine and, 84
environmental enrichment and, 14
epigenetics and, 34
Rett syndrome and, 40, 55, 61
B
Behavior
attachment behavior and, 118–126, 130
eyear behavior in primates, 162–165
eyear environmental modulation and, 48, 54, 152, 185, 191, 193
emotional behavior, 150, 174, 177–178
environmental enrichment and, 13–14
infant behavior in primates, 164
institutionalization and, 193
social behavior, 50, 193
see also maternal behavior and stress
Benzodiazepine, 84
see also antidepressant
Beta-amyloid, 11
Beta-endorphins, 177–178
Binocularity
environmental enrichment and, 15–16
Bipolar disorder, 48, 57–58
Blindness, 9, 217
Blood-brain barrier, 85
Bonding, 14
Bowlby, John, 117
see also attachment
Brain damage
- critical periods and, 139
- Brain-derived neurotrophic factor (BDNF)
  - antidepressants and, 52–53, 149
  - environmental enrichment and, 6–9, 17, 49–51
  - maternal care and, 126–127, 147–149, 151–153
- microRNA and, 38
- prenatal enrichment and, 11
- prenatal stress and, 54, 150, 154
- related polymorphisms, 173, 199
- relation with other neurotrophins, 142–145
- Rett syndrome and, 57, 59–61, 145–146
- visual system development and, 8–9

Brainstem, 76, 90.

Bumetanide, 84–85

C
- Cadherins, 108
- Calcium
  - early experience and, 141
  - imaging of, 139
- cAMP, 104–105, 128
- Cataract, 36
- Central nervous system (CNS)
  - dopamine and, 168
  - environmental enrichment and, 6, 9, 12, 20
  - microRNA and, 39
  - neurodevelopmental disorders and, 74
  - NGF and, 142
  - stress and, 164
- Cerebellum, 57, 60, 107
- Cerebral cortex, 6, 9, 147
- Chondroitin sulphate proteoglycans, 4, 13
- Chromatin
  - epigenetic changes and, 28–32, 34–36, 41, 53
  - influence of maternal care on, 99, 101, 104, 125, 153
  - Lynx proteins and, 5
  - MeCP2 and, 57
  - neuroplasticity and, 26,
- Cocaine, 33
- Cognition
  - environmental enrichment and, 14
  - epigenetics and, 34
  - institutionalization and, 188, 206–207
- Cognitive impairment, 13–14, 86, 203
- Communal nesting, 147, 150
- Conditioning, 33, 119, 122, 123–124, 129
  - see also fear conditioning
- Contrast sensitivity
  - amblyopia and, 3, 15
- Coping response, 148, 152
- Corpus calosum, 195
- Corticosterone, 50–54, 59–61, 122–123, 130
  - see also stress
- Corticotropin-releasing hormone (CRH), 52, 60, 165, 173, 179
- Cortisol
  - early abuse and, 171
  - effects of massage on, 216
  - HPA and, 52, 165, 198
  - infant behavior and, 163–165
  - institutionalization and, 199
  - maltreatment and, 125
  - opioid polymorphisms and, 178
  - serotonin polymorphism and, 175
  - see also stress
- CREB-binding protein (CBP), 32, 34, 105, 141
- Critical periods
  - BDNF and, 144
  - definition and key examples, 1, 2, 4, 35, 139
  - epigenetic control of, 38–39, 41
  - neurodevelopmental disorders and, 73, 80, 82–87, 89–91
  - reopening in adult rodents, 15–18, 36
  - see also sensitive periods
- Cues
  - brain development and, 73, 75, 76
  - early experience and, 27
  - early life trauma and, 130
  - maternal influence and, 100, 102, 128
- Cytosine, 30–31, 99–100, 103, 125, 174
  - see also DNA methylation
- Deprivation
  - maternal stress and, 122
  - stress and, 141
  - visual development and, 1–2, 4–5, 35, 40
  - see also institutional deprivation, maternal deprivation, monocular deprivation, social deprivation
- Diazepam, 17
- Diet, 53–54, 119, 152
- Discrimination threshold, 19
- Disease
  - animal models and, 47–50
  - environmental enrichment and, 20
  - epigenetics and, 34, 37
  - MeCP2 and, 55, 57–58
  - neurotrophins and, 145
  - somatic mutations and, 56–57
- Distress vocalization, 164, 175–177
- DNA methylation
  - chromatin remodeling and, 28, 30–31, 34, 53
  - maternal care and, 99–107, 110–112
  - relation with caregiver maltreatment, 124–125, 127 153–154, 176, 200
  - visual cortex and, 41
- DNA methyl-transferase, 30
  - see also DNA methylation
- Dopamine
  - depression and, 54
related polymorphisms, 178–179
stress reactivity and, 163–164, 173
Double cortex syndrome, 85
Down syndrome
environmental enrichment and, 13, 14, 49
genetic intervention and, 84–85
MeCP2 and, 55
spine morphology and, 79, see also Ts65Dn mice

E
EEG, 196–197
infant massage and, 218–220
Embryogenesis, 99
Emotions, 52, 74, 146, 150, 163
non-human primate development and, 168,
173, 177, 179
institutionalization and, 191
infant attachment and, 117–118
Enriched environment
see environmental enrichment
Environment
DNA methylation and, 103, 106, 108, 110
enriched environment and, 6–7, 9–11, 13–15
epigenetics and, 53
infant development and, 117–119, 123–125,
128, 130, 140, 146–147, 153–154, 171, 173,
interaction with the genotype, 47–48, 174–176,
180
social environment, 103, 108, 110, 150–151,
153, 161–163, 166, 194
see also environmental enrichment
Environmental enrichment (EE)
adult brain plasticity and, 14–20
BDNF and, 6–9, 11, 17, 52–53
behavioral beneficial effects, 49
brain development and, 6–11, 13–14
components of, 49–51
definition and peculiarities, 5–6, 49
Down syndrome and, 13, 14, 49
gene expression and, 51
gene-environment interaction and, 55
massage therapy and, 217–218
maternal care and, 9–11, 54
MeCP2 and, 59–61
prenatal effects, 11–12
stress and, 53, 150, 152
visual development and, 6–11
visual system plasticity and 1–20,
Epigenetic programming, 104–107, 109, 111–112
infant attachment and, 124–125, 128
Epigenetics, 28, 31, 53, 99, 152, 199
Epigenome, 34, 40–41, 200
Epilepsy, 74, 79, 84
Exercise, 5, 11–12, 17, 49–51, 54, 60
Experience
epigenetics and, 35–40, 102–109
infant development and, 187–188, 201, 215
non-human primate development and, 161
visual development and, 5–9 15–18
Extracellular matrix, 4, 13, 36
Extracellular signal-regulation kinase 1,2 (ERK),
29, 31, 36, 128
Eye opening
enrichment and, 8
visual system development and, 35, 38–39
F
Fear conditioning, 33
Fetus, 7, 11–12, 215
Field, Tiffany, 216–217
Fluoxetine, 17
Food, 5, 13, 119, 152
Foster care
child performance and, 187–188
institutionalization and, 192–193, 195, 198,
201–202, 206
Fragile X Mental Retardation Protein (FMRP),
81–84
Fragile X Syndrome, 34
critical periods and, 77–78
DNA methylation and, 31
environmental enrichment and, 14, 49
epilepsy and, 88
GABA and, 88
protein synthesis and, 82, 89
Freud, Sigmund, 118
G
GABAergic inhibition, See GABA
Gamma-aminobutyric acid (GABA), 5
critical periods and, 83–85
early experience and, 141, 144–145
environmental enrichment and, 7–8, 13–14,
16–18, 20
Fragile X syndrome and, 78, 88
maternal long-term effects on, 149, 151
MeCP2 and, 58
stress and, 52
Gene expression, 27
critical periods and, 83
DNA methylation and, 100–101 104, 108
epigenetic control of, 31–36, 53–55 152
Gene therapy, 58
Gene-environment interaction, 27, 47–48, 53, 61,
125, 162, 180
see also genotype
Genome
chromatin remodeling and, 31
histone acetylation and, 33–35
synaptic plasticity and, 34
psychiatric disorders and, 48
Rett syndrome and, 57
epigenetics and, 99–101, 110–112
Genotype
depression and, 149
epigenetics and, 99–100
gene-environment interaction and, 55
neurotrophins and, 152
schizophrenia and, 54
serotonin polymorphisms and, 171–172,
175–177
single nucleotide polymorphisms and, 199
see also gene-environment interaction and genotype
Glial cells, 40
Glucocorticoid, 50–52, 104, 140, 165
receptor of, 101, 104, 126, 128, 153, 173
Glutamate, 13, 16, 31, 57–58, 81–82, 144
Glycine, 37
Granule cell, 147, 150
Gratings, 18–20
Grooming, 10, 142
beta-endorphins and, 177
DNA methylation and, 53, 103, 105, 126
infant attachment and, 120, 123
long-term effects of, 130
MeCP2 and, 61
self-directed behavior and, 163
tactile stimulation and, 217
GTPase, 40, 81–82

**H**
Handling
definition, 140
infant maltreatment and, 123, 130, 171
infant massage and, 216
interaction with the genotype, 175
long-term effects of, 141, 150
prefrontal cortex and, 194
Harlow, Harry, 121
Hippocampus, 11
critical periods and, 151, 153
environmental enrichment and, 11, 13
epigeneic effects and, 31–33, 39, 49, 52
Fragile X syndrome and, 78–79
institutionalization and, 196
LTP and, 20
prenatal stress and, 150
Rett syndrome and, 57–58
stress and, 52–53, 126
Histone deacetylase, 29, 57, 101, 154
see also histones
Histones, 5, 28
critical periods and, 36, 38–40
DNA methylation and, 125
epigeneic changes and, 28–34, 53, 174
MeCP2 and, 57
mood control and, 154
see also histone deacetylases
Hormone, 163–164, 172
see also adrenocorticotropic hormone, glucocorticoid, cortisol
Hospitalization, 14
Hubel, David, 1, 3, 5, 139
Huntington’s disease, 48–50
Hyper-activity disorder (ADHD), 189–190, 195, 196, 199
institutionalization and, 204
Hypospastic-putititary-adrenal (HPA) axis
see stress
Hypothalamus, 13, 52, 140, 147, 165

**I**
Impoverishment, 14, 216

Infant massage
see massage
Infant’s attachment
see attachment
Infanticide, 166
Inflammation, 51
Inhibition, 8, 13, 17–18, 20, 78, 144–145
Down syndrome and, 14–15
brain plasticity and, 17–18, 20, 40, 83–88, 88–89
see also GABA
Institutional deprivation, 4, 185–207
see also institutionalization
Institutionalization, 185–186
ADHD and, 189–190, 195, 196, 199, 204
effects on amygdala, 196
effects on cognition, 188
effects on EEG, 197
effects on emotions, 191
effects on executive functions, 189
effects on prefrontal cortex, 186–187
language development and, 186, 190, 193, 200, 205
sensitive periods and, 187
stress and, 198
Insulin-like growth factor-1 (IGF-1), 7–12
infant massage and, 219
Intellectual disability, 74
see also mental retardation

**K**
Kangaroo care, 216

**L**
Language
critical periods and, 3–4
institutionalization and, 186, 190, 193, 200, 205
neurodevelopmental disorders and, 58, 74
Lateral geniculate nucleus (LGN), 20
Lazy eye, 15, 16, 36
see also amblyopia
Learning
attachment and, 3, 117–127
critical periods and, 4
Down syndrome and, 13
environmental enrichment and, 49
epigenetics and, 32
institutionalization and, 190
LTP and, 20
microRNA and, 37
prenatal stress and, 150
putamen and, 187
Rett syndrome and, 34, 60
see also attachment learning, memory, perceptual learning
Leptin, 12
Levi-Montalcini, Rita, 142
Levine, Seymour, 140–141
Licking, 10, 142
dNA methylation and, 53, 103, 105, 126
long-term effects of, 130
MeCP2 and, 61
tactile stimulation and, 217
Limbic system, 195
Locus coeruleus
attachment learning and, 120, 122
Long-term depression (LTD)
epigenetics and, 31
depression and, 147
Long-term potentiation (LTP)
BDNF and, 143
epiphanies and, 5, 8, 13
epigenetics and, 31
perceptual learning and, 18–20
Rett syndrome and, 58
Lynx protein, 5

M
Maltreatment, 123–128, 149, 153, 170, 203–204
MAPK, 31, 128
Massage
effects in rodents, 10, 14
effects in babies, 215–221
Maternal behavior, 142, 166
attachment learning and, 119,
environmental enrichment and, 7, 147, 150
epigenetics and, 28, 103–106
in non human primates, 109
infant abuse and, 130
variability in non human primates, 162, 167, 170
visual system development and, 10–11
see also maternal care
Maternal care, 3, 53, 54, 117, 128, 141, 150, 153, 168
environmental enrichment and, 7
epiphanies and, 99–110
see also maternal behavior
Maternal deprivation, 50, 141, 147, 177, 194
effects in non human primates, 109–110, 112, 195
see also maternal separation
Maternal enrichment, 12
see also environmental enrichment
Maternal separation, 110, 118, 141, 145, 147, 149
evironmental enrichment and, 150
paradigm in infant primates, 164, 175–176, 178, 194
see also maternal deprivation
Maternal stimulation, 10, 12
see also maternal care
McCP2, 14, 34, 39–40, 55–61, 101, 145
see also Rett Syndrome
Memory
attachment and, 120, 123
BDNF and, 145
Down syndrome and, 14
environmental enrichment and, 49–50
Epigenetics and, 31–33
fear memory, 3
microRNA and, 37, 39
Stress and, 150
working memory, 189
see also learning
Mental retardation, 13, 32, 34, 81–82
see also intellectual disability
Mental stimulation, 54
see also environmental enrichment
Metabolism, 165, 174, 196
Metabotropic glutamate receptor, 81–82
Methylation
see DNA methylation
Methyltransferase, 33, 54, 100–101, 106
MicroRNA, 37, 39–40, 99, 101
Monoamine oxidase A (MAOA), 173, 176
Monoamine, 163, 168, 173, 176
Monocular deprivation, 2, 16–17, 35, 79
Mood disorder, 146, 148–149
Motor cortex, 6, 20, 58
Motor skills
neurodevelopmental disorders and, 74
Music
adult brain plasticity and, 41
critical periods and, 3
therapy and, 58
Myelin, 4

N
Nature and nurture, 6, 100
Neglect, 146, 196, 204
Neonatal intensive care unit (NICU), 216–219
Nerve-growth factor (NGF)
central nervous system development and, 142–144
eyear experiences and, 147, 150
environmental enrichment and, 60
Neurodegenerative disorder, 48, 139
Neurodevelopmental disorder, 47–49, 53, 73, 154
Neurogenesis, 14, 50–52, 147–148, 152
Neuroimaging, 197
Neuronal activity, 57, 59, 73, 85, 102, 144
infant massage and, 219–220
Neuropeptide Y (NPY), 164, 173, 179
Neuropeptide, 163–164, 173, 179
Neuroplasticity, see plasticity
Neurotrophic factors, 20
see also neurotrophins
Neurotrophins, 51–52, 59, 150, 152
action as mediators of early life event effects, 143–146
brain plasticity and, 141–143
see also neurotrophic factors
NGF, 104–105, 107
N-methyl-D-aspartate (NMDA) receptor
developmental expression, 78–79, 81
environmental enrichment and, 54
LTP and, 31
neurotrophins and, 144
Nogo, 4, 196, 198
Noradrenalin
attachment learning and, 120, 122
stress response and, 163–164
NT-4/5, 142
Nucleus accumbens
drug addiction and, 33
Nutrition, 10, 186, 188, 190, 203
O
Ocular dominance
  critical periods and, 1–3, 35, 40, 75, 79
  Down syndrome and, 14
  environmental enrichment and, 17, 75, 79
  Fragile X Mental Retardation Protein and, 82–83
  orientation selectivity and, 9
  see also plasticity
Odor
  infant attachment and, 119–124, 128–129
  Olfactory bulb
    attachment learning and, 120, 122–123
  ON/OFF sublaminae, 9
Opioid, 17
  related polymorphisms, 177–178
Orphanage, 188, 193, 195–196, 202–203
Oxytocin, 84, 177
P
p75, 51, 142–144
Pain
  infant attachment and, 118, 121–124, 169
Parvalbumin, 40, 141
Pavlov, Ivan, 122
  see also conditioning
Perceptual learning, 18–19
Perineuronal nets (PNNs), 4
Phenotype
  attachment learning and, 128
  CBP gene and, 32
  communal nesting and, 151
  Down syndrome and, 13–14, 84
  drug addiction and, 33
  epigenetics effects on, 103–107
  Fragile X syndrome and, 78–80
  handling and, 140
  hyperexcitability and, 88, 89
  institutional care and, 186
  natural disasters and, 110–112
  neurotrophins and, 144–145, 152
  relation with genotype, 99
  Rett syndrome and, 56, 58, 60
  rodent models of, 48
  see also genotype
Phospholipase C, 128
Physical exercise, 5, 11–12, 17, 49–51
Piriform cortex, 120, 123
Placenta, 7, 11–12, 85
Plasticity
  attachment and, 120, 123, 126
  BDNF and, 7, 9
  brain development and, 27, 139
  critical periods and, 1–4, 75–76
  early experience and, 140–141, 143–155
  environmental enrichment and, 14–20, 51, 60, 150, 217
  epigenetics and, 31–40
  Fragile X syndrome and, 78, 82
  institutional care and, 185, 187–190, 200, 202–203, 205–207
  MeCP2 and, 58
  neurodevelopmental disorders and, 80, 89
  neurotrophins and, 143, 146–149, 152
  stress and, 196
  see also ocular dominance
Play
  free play task, 164, 173, 175
  social play, 163, 167–168
Polymorphism, 55, 148, 162, 173–175, 177–179, 199
Post-traumatic stress disorder, 125
Prader-Willi syndrome, 55, 86
Prefrontal cortex, 52, 78, 88, 120, 147, 153
  differential rearing effects on, 109, 194
  maltreatment/institutional care and, 127, 186–187, 189, 195–196
Prenatal enrichment, 11, 12
Prenatal stress, 11, 54, 111, 141, 154, 204
Preterm infant, 10, 215–221
Prolactin, 175
Protein kinase A (PKA)
  maternal care and, 104
Protein synthesis, 82, 107
Protocadherin genes, 108
Psychiatric disorders, 48, 61
  attachment trauma and, 124–125, 127, 130
  epigenetic therapeutics and, 107
  gene-environment interactions and, 55–56
  neurotrophins and, 146, 148–149
  social isolation and, 50
  stress and, 53
Purkinje neurons, 60
Putamen, 187
Pyramidal neurons
  BDNF and, 145
  neurodevelopmental disorders and, 78–79
  prefrontal cortex and, 194
  Rett syndrome and, 57–59
R
Rac1, 40, 81–82
Rejection
  maternal rejection in primates, 165–170, 172, 179
  maternal rejection in rodents, 130
Resilience
  environmental enrichment and, 49
  stress development and, 169, 172
  institutionalization and, 190, 200, 204–205
Retina, 7, 9, 11–12, 86, 90
Retinal ganglion cells, 7
Retinitis pigmentosa, 9
Rett Syndrome, 14, 31, 34, 40, 49–50, 55–56, 58, 61, 101, 145
  see also MeCP2
Reverse suture, 16
Rubinstein-Taybi syndrome, 34
S
Sensitive periods, 36, 39, 41, 73–77, 118, 120
Index

institutionalization and, 187, 200
see also critical periods
Serotonin
anxiety and, 149
depression and, 149
emotional behavior and, 163–164
maternal care and, 104–105
related polymorphisms, 148, 171, 174–177
Shock, 140
infant attachment and, 121–122, 124, 128–130
Single nucleotide polymorphism (SNP), 55, 148, 173, 177–178
in children, 199
Sleep, 152, 193, 216, 219–220
Social isolation, 50, 54,
Somatosensory cortex, 58–59, 75–76, 78
Sound sensitivity, 13
Speech abilities, 3, 74
Spines
environmental enrichment and, 5
epigenetics and, 32, 38–40
neurodevelopmental disorders and, 77–83, 85
neurotrophins and, 144–145
Rett syndrome and, 57
see also dendritic spines
Serotonin re-uptake inhibitors (SSRIs), 149
Stereopsis, 3, 14–16
Stereotypic behavior, 86, 90, 164, 175, 193
Strabismus, 15, 36
Stress, 5, 28–29, 49–55, 59, 218
amygdala and, 196
institutionalization and, 201, 204–206
maternal abuse and, 171
maternal effects on, 100, 102, 104–106, 108, 153, 205–206
maternal stress and, 110–111, 122
neurotrophins and, 146–149
reactivity in primates, 161–165, 169, 171–179
stress regulation system, 123–127, 141, 198
see also prenatal stress
SUMOylation, 28–30
Synapses
BDNF and, 51, 144–145
critical periods and, 76
environmental enrichment and, 13
maternal care and, 107
neurodevelopmental disorders and, 82, 85–87
Rett syndrome and, 57
Synaptic density, 5, 40, 54, 57
Synaptic plasticity
BDNF and, 148
critical periods and, 76–78
Down syndrome and, 14
environmental enrichment and, 14, 51
epigenetics and, 31–32, 34
Fragile X syndrome and, 78, 83
glutamate receptors and, 78, 82
infant attachment and, 126
MeCP2 and, 58
neurotrophins and, 144
p75NTR and, 143
Synaptogenesis, 61, 108
Synaptophysin, 6, 150
T
Telomere, 127–130
institutionalization and, 200
Thalamus, 13, 20, 76, 78
see also hypothalamus
Transcriptome, 40, 108
Trauma, 118, 124, 128, 130, 146, 170
Trichostatin A (TSA), 32, 36, 39, 104, 106, 108
TrK, 143–145
Ts65Dn mice, 13–14, 85
see also Down syndrome
Twins, 57
V
Valproic acid, 36, 84–85, 90, 154
Vasopressin, 164
Ventral tegmental area, 54
Videogames, 18
Visual acuity, 3, 35–36, 140
environmental enrichment and 7–8, 10, 14–17
infant massage and, 218–219
Visual cortex
BDNF and, 144
critical periods and, 1–2, 79, 139
environmental enrichment and, 7–10, 14–18, 150
epigenetics and, 27, 35–36, 38–41
glutamate and, 82
infant massage and, 218–219
Visual evoked potentials, 10, 218
Visual system
critical periods and, 86, 139
environmental enrichment and, 6–10, 14–15, 18, 150
epigenetics and, 34
infant massage and, 219
W
Wiesel, Torsten, 1, 3, 5, 139